Author

Juan David Florez Arango

Observed names: J.D. Florez Arango, J.D. Florez-Arango, Juan David Florez-Arango, Juan David Flórez-Arango, Juan Florez-Arango, Juan Flórez-Arango, Juan-David Florez-Arango

Institution: Instituto de Cancerología Las Américas

Observed institutions: Inserm, Université Paris-Saclay, Institut Gustave Roussy, Instituto de Cancerología Las Américas

ORCID: 0009-0004-4531-6495

Observed ORCID: 0009-0004-4531-6495

OpenAlex ID: A5020436377

Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer

2023 · Francesco Facchinetti, Antoine Hollebecque, et al. · Cancer Discovery · 91

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development

2024 · Damien Vasseur, Ludovic Bigot, et al. · Molecular Cancer · 13

PDF

Pathomics-based prediction of thymic epithelial tumor subtypes within the French RYTHMIC network.

2025 · Lodovica Zullo, Mathilde Bateson, et al. · Journal of Clinical Oncology · 1

425P: Real-world data of everolimus in patients with thymic epithelial tumors (TETs)

2025 · Á. López Gutiérrez, J.D. Florez Arango, et al. · Journal of Thoracic Oncology · 1

PDF

424P: Real-world data of lenvatinib in patients with thymic epithelial tumors (TETs)

2025 · Á. López Gutiérrez, J.C. Benitez Montanez, et al. · Journal of Thoracic Oncology · 1

Data from Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer

2024 · Francesco Facchinetti, Antoine Hollebecque, et al. · 1

Supplementary Table 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

2023 · Francesco Facchinetti, Antoine Hollebecque, et al. · 1

Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

2023 · Francesco Facchinetti, Antoine Hollebecque, et al. · 1

Lenvatinib for the treatment of thymic epithelial tumors (TETs): A real-life multicenter experience.

2022 · Jose Carlos Benitez, Juan Florez-Arango, et al. · Journal of Clinical Oncology · 1

P1.368: Immune Checkpoint Inhibitor-Based Therapy in PD-L1-Negative Advanced NSCLC: Real-World Outcomes From a Latin American Multicenter Cohort

2026 · R. Amorin, C.R. Picon, et al. · Journal of Thoracic Oncology

Hsd61 Sociodemographic and Clinical Factors Associated With Time to Treatment Initiation and Care Pathways in Non-metastatic Non-small Cell Lung Cancer (nsclc) in Colombia: a Real-world Evidence Study

2026 · Iader Alfonso Rodríguez-Márquez, Melissa Diaz Puentes, et al. · Value in Health

Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer